Porcilis ERY

Hauptinformation

  • Handelsname:
  • Porcilis ERY Injektionssuspension
  • Darreichungsform:
  • Injektionssuspension
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Porcilis ERY Injektionssuspension
    Belgien
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • AFMPS - Agence Fédérale des Médicaments et des Produits de Santé - Belgium
  • Zulassungsnummer:
  • BE-V328614
  • Letzte Änderung:
  • 17-04-2018

Packungsbeilage

Bijsluiter – DE Versie

Porcilis Ery

B. PACKUNGSBEILAGE

- 1 -

Bijsluiter – DE Versie

Porcilis Ery

1.

NAME

UND

ANSCHRIFT

DES

ZULASSUNGSINHABERS

UND,

WENN

UNTERSCHIEDLICH, DES HERSTELLERS, DER FÜR DIE CHARGENFREIGABE

VERANTWORTLICH IST

Intervet International B.V. – Boxmeer – die Niederlande vertreten durch

MSD Animal Health BVBA - Lynx Binnenhof 5 - 1200 Brussel

2.

BEZEICHNUNG DES TIERARZNEIMITTELS

PORCILIS

®

ERY

3.

ARZNEILICH WIRKSAME(R) BESTANDTEIL(E) UND SONSTIGE BESTANDTEILE

Erysipelothrix rhusiopathiae (Stamm M2 serotyp 2) inactiv.

50 IU - dl-α-Tocopherol Acetat pro

dos. un. (2 ml).

4.

ANWENDUNGSGEBIET(E)

Zur aktiven Immunisierung von Schweinen gegen Erysipelothrix rhusiopathiae (Serotyp 1 und 2)

zur Verringerung der klinischer Symptome von der Fleckkrankheit.

Beginn der Immunität : 3 Wochen.

Dauer der Immunität : 3 Monaten.

5.

GEGENANZEIGEN

Nicht bekannt, wenn vorschriftsmäßig verwendet. Nur gesunde Tiere impfen.

6.

NEBENWIRKUNGEN

Nach der Impfung kann bei einer gewissen Anzahl an Tieren vorübergehend leichtes Fieber

auftreten, das mit Lustlosigkeit und einem zeitweiligen Anschwellen an der Injektionsstelle

einhergeht. Diese Nebenwirkungen vergehen innerhalb 1-4 Tage nach der Impfung.

7.

ZIELTIERART(EN)

Schwein.

8.

DOSIERUNG FÜR JEDE TIERART, ART UND DAUER DER ANWENDUNG

Dosis: 2 ml pro Tier.

Darreichungsweise:

Erstimpfung: 2 Injektionen ab 12 Wochen, mit 4-wöchiger Zwischenzeit.

Auffrischungsimpfung:

Säue: 1 Dosis während jeder Säugeperiode.

Eber: 2 Impfungen pro Jahr (jede 6 Monate).

Jungsäuen und Eber während der letzten zwei Wochen vor dem Decken

nicht impfen.

Tief intramuskulär hinter das Ohr injizieren.

- 2 -

Bijsluiter – DE Versie

Porcilis Ery

9.

HINWEISE FÜR DIE RICHTIGE ANWENDUNG

Vor Impfung den Impfstoff Raumtemperatur (15 bis 25°C) erreichen lassen. Nur steriles

Injektionsmaterial verwenden.

Vor und während Gebrauch gut schütteln.

10.

WARTEZEIT

Fleisch: 0 Tage.

11.

BESONDERE LAGERUNGSHINWEISE

Dunkel bei 2 bis 8°C. Nicht einfrieren.

Haltbarkeitsdatum

24 Monate haltbar. Siehe das Verfalldatum auf der Auβenverpackung vorabgegangen mit "Ex.:".

Um die Sterilität zu gewährleisten, eine angebrochene Flasche innerhalb von 10 Stunde

aufbrauchen.

12.

BESONDERE WARNHINWEISE

Nicht bekannt, wenn vorschriftsmäßig verwendet.

Porcilis Ery kann während der Trächtigkeit verwendet werden.

13.

BESONDERE VORSICHTSMASSNAHMEN FÜR DIE ENTSORGUNG VON NICHT

VERWENDETEM ARZNEIMITTEL ODER VON ABFALLMATERIALIEN, SOFERN

ERFORDERLICH

Es sind die erforderlichen Vorkehrungen zu einer umweltgerechten Entsorgung zu treffen.

14.

GENEHMIGUNGSDATUM DER PACKUNGSBEILAGE

12/2012.

15.

WEITERE ANGABEN

Auf tierärztlicher Vorschrift.

BE-V180713

BE-V328614

- 3 -

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse

FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse

U.S. Marshals Service has conducted a mass seizure of FDA-regulated products that were being held in an Arkansas grocery warehouse under insanitary conditions

FDA - U.S. Food and Drug Administration

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

22-6-2018

Dringende Sicherheitsinformation zu Geratherm Patient Warming System UniqueTemp° Recovery, Recovery Set 1 von Geratherm Medical AG

Dringende Sicherheitsinformation zu Geratherm Patient Warming System UniqueTemp° Recovery, Recovery Set 1 von Geratherm Medical AG

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

14-6-2018

ANSES consolidates its presence in Boulogne-sur-Mer!

ANSES consolidates its presence in Boulogne-sur-Mer!

Centrally located in the port of Boulogne-sur-Mer, the Laboratory for Food Safety's site specialising in fishery and aquaculture products is expanding! This extension, financed jointly by the Hauts-de-France Region and the local community, underlines ANSES's scientific investment in Boulogne-sur-Mer and is fully consistent with regional research dynamics for the quality and safety of aquatic products.

France - Agence Nationale du Médicament Vétérinaire

13-6-2018

Carmen Jewellery Inc. recalls Kenneth Cole-branded men's watches

Carmen Jewellery Inc. recalls Kenneth Cole-branded men's watches

The clear domed crystal glass on the watch face may detach or shatter, posing a physical or laceration hazard.

Health Canada

17-5-2018

The Michaels Companies, Inc. recalls Creatology Pottery Wheel Kit and Creatology Spin Art Kit

The Michaels Companies, Inc. recalls Creatology Pottery Wheel Kit and Creatology Spin Art Kit

Internal wiring within the product may overheat posing a risk of burns or fire.

Health Canada

20-6-2011

Warning against the tanning product Melanotan

Warning against the tanning product Melanotan

The Danish Medicines Agency repeats its warning against using the illegal product Melanotan because its effect is not documented and because of the absence of studies of its potential side effects. The Danish Medicines Agency urges everyone who uses Melanotan to stop using it and to contact their doctor if concerned.

Danish Medicines Agency

23-10-2018

Loceryl® Creme

Rote - Liste

19-9-2018

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery.

More on filing a flood insurance claim:  http://fema.

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.gov/nfip-file-your-claim … pic.twitter.com/lv5Na8Zw8c

FDA - U.S. Food and Drug Administration

19-9-2018

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery:

Call 2-1-1 to connect with local sources of help.
 http://DisasterAssistance.gov  connects you with federal or volu

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery: Call 2-1-1 to connect with local sources of help. http://DisasterAssistance.gov  connects you with federal or volu

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery: Call 2-1-1 to connect with local sources of help. http://DisasterAssistance.gov  connects you with federal or voluntary organization resources. pic.twitter.com/UYuxr0yvF0

FDA - U.S. Food and Drug Administration

25-8-2018

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety  https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.gov/xUuSb  #OnePairTakeCare pic.twitter.com/hNCAOAmJVQ

FDA - U.S. Food and Drug Administration

22-8-2018

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevice pic.twitter.com/SQYFz30oFy

FDA - U.S. Food and Drug Administration

22-7-2018

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

FDA - U.S. Food and Drug Administration

16-7-2018

Loceryl® Nagellack gegen Nagelpilz

Rote - Liste

29-6-2018

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7

Europe -DG Health and Food Safety

26-6-2018

Cost recovery implementation statement

Cost recovery implementation statement

Updated to include new fees and charges effective 1 July 2018

Therapeutic Goods Administration - Australia

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety